Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Mol Carcinog. 2010 May;49(5):500–507. doi: 10.1002/mc.20600

Figure 3.

Figure 3

Benzyl isothiocyanate (BITC) administration reduced cell proliferation and suppressed angiogenesis in MDA-MB-231 tumors (subcutaneous study with i.p. BITC administration). (A) expression of Ki-67, (B) TUNEL-positive apoptotic bodies, and (C) CD31-positive blood vessels (identified by an arrow) in representative tumor section of a mouse of both the control group and the 7.5 μmol BITC treatment group (400× magnification). Columns, mean (n= 4-5 tumor sections from different mice); bars, SE. Statistical significance compared with control was determined by the Student's t-test.